Table 2.
Analysis of the IgA concentration in CSF and serum samples from MS patients and control groups.
| NonMSDND | NDND | MS | CIS | RR | SP | PP | |
|---|---|---|---|---|---|---|---|
| (n = 23) | (n = 30) | (n = 151) | (n = 56) | (n = 50) | (n = 24) | (n = 21) | |
| Serum IgA (mg/dL) | |||||||
| Mean ± SEM | 272.46 ± 42.39 | 224.84 ± 28.54 | 144.95 ± 8.55 | 162.74 ± 16.34 | 137,72 ± 13.75 | 108.99 ± 12.13 | 155.81 ± 23.70 |
| Minimum | 30.23 | 6.25 | 9.43 | 9.43 | 19.01 | 31.70 | 19.00 |
| Maximum | 959.16 | 458.87 | 764.47 | 764.47 | 646.10 | 256.00 | 427.00 |
| CSF IgA (mg/dL) | |||||||
| Mean ± SEM | 0.232 ± 0.035 | 0.195 ± 0.026 | 0.71 ± 0.60 | 0.11 ± 0.015 | 0.101 ± 0.014 | 0.070 ± 0.015 | 4.48 ± 4.28 |
| Minimum | 0.084 | 0.012 | 0.002 | 0.002 | 0.006 | 0.010 | 0,01 |
| Maximum | 0.632 | 0.504 | 90.09 | 0.51 | 0.620 | 0.295 | 90.09 |
| Serum albumin (g/L) | |||||||
| Mean ± SEM | 4.03 ± 0.10 | 4.18 ± 0.09 | 4.42 ± 0.04 | 4.56 ± 0.06 | 4.47 ± 0.06 | 4.21 ± 0.09 | 4.15 ± 0.09 |
| CSF albumin (mg/L) | |||||||
| Mean ± SEM | 21.16 ± 2.46 | 21.31 ± 4.19 | 20.68 ± 0.66 | 19.20 ± 0.92 | 20.17 ± 1.03 | 24.79 ± 2.29 | 21.14 ± 1.62 |
| Positive IAS calculated by Reibergram | |||||||
| 14.29% | 14.29% | 16.78% | 16.07% | 12.50% | 16.67% | 23.81% | |
NonMSDND Non-MS demyelinating neurological diseases, NDND non-demyelinating neurological diseases, MS multiple sclerosis patients, CIS clinically isolated syndrome, RRMS relapsing–remitting multiple sclerosis, SPMS secondary progressive multiple sclerosis, PPMS primary progressive multiple sclerosis, SEM standard error of the mean, IAS intrathecal IgA synthesis.